Supernus Announces Preliminary Second Quarter 2020 Revenue
- Second quarter total revenue is estimated to be
$126.7 million, a 21% increase over 2019
- Net product sales of Trokendi XR® and Oxtellar XR® are estimated to be
$113.4 million, an 11% increase over 2019
- Completed acquisition of CNS portfolio of
US WorldMedson June 9, 2020
- Management to host a conference call and webcast to review full second quarter 2020 results on
Wednesday, August 19, 2020at 9:00 a.m. ET
Preliminary second quarter 2020 revenue consisted of net product sales of
|Net Product Sales
($ in millions)
|Q2 2020||Q2 2019||Change %|
The second quarter 2020 revenue results included herein are preliminary and are therefore subject to change.
Conference Call Details
The Company expects to report full second quarter 2020 results after
|Conference dial-in:||(877) 288-1043|
|International dial-in:||(970) 315-0267|
|Conference Call Name:||Supernus Pharmaceuticals Second Quarter 2020 Earnings Conference Call|
Following the live call, a replay will be available on the Company's website, www.supernus.com, under “Investor Relations”.
APOKYN Pen and the apomorphine infusion pump product candidate licensed from
XADAGO is licensed from
All trademarks are the property of their respective owners.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information, but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products; the Company’s ability to increase its net revenue; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates; the Company’s ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; and other risk factors set forth from time to time in the Company’s filings with the
Tel: (301) 838-2591
Office: (443) 213-0505
Mobile: (443) 377-4767
Source: Supernus Pharmaceuticals, Inc.